P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE‐POSITIVE OR RELAPSED/REFRACTORY B‐CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
Chiaretti, Sabina, Blum, Sabine, Leguay, Thibaut, Balsat, Marie, Salek, Cyril, Fracchiolla, Nicola, Spyridonidis, Alexandros, Rijneveld, Anita, Papayannidis, Cristina, Ganzha, Sofia, Bhattacharyya, Reetabrata, Zugmaier, Gerhard, Pezzani Grueter, Isabella, Ochs, Andreas, Rambaldi, Alessandro
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD+) B-ALL in a phase 4 study
Pardee, Timothy S., Varela, Juan, Jeyakumar, Deepa, Keng, Michael Kenneth, Bar-Natan, Michal, Gundabolu, Krishna, Gayle, Arlene, McCann, Christopher, Xia, Qing, Ganzha, Sofia, Mergen, Noemi, Zaman, Faraz, Gordon, Paul R., Khan, Sharif S.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article